WAVE LIFE SCIENCES LTD. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
WAVE LIFE SCIENCES LTD. (WVE) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $30.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-07-30
- WAVE LIFE SCIENCES LTD. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00.
- WAVE LIFE SCIENCES LTD. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00.
- WAVE LIFE SCIENCES LTD. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $12.01M, a 166.92% increase from fiscal 2021.
- WAVE LIFE SCIENCES LTD. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $4.50M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.02M 10-Q · filed 2026-07-30 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-07-30 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $0.00 derived: sum of 2 quarters · filed 2025-03-04 | $12.01M 10-K · filed 2025-03-04 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $12.01M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $12.01M 10-Q · filed 2023-08-03 | |||
| 2021-12-31 | $4.50M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |